Anti -Myosin Light Chain 2, phosphorylated (Ser19) (MLC2, Myosin Regulatory Light Chain, MRLC, RLC, LC20)

For Research Use Only. Not for use in diagnostic procedures.

Chromosome: 12; NC_000012.11 (111348623..111358404, complement). Location: 12q24.11

Monoclonal

IgG1

4i15

Mouse

Recognizes endogenous levels of human Myosin Light Chain 2 (smooth muscle) at ~18kD only when phosphorylated at serine 19.

Ascites

Supplied as a liquid in 10mM sodium HEPES, pH 7.5, 150 mM sodium chloride, 0.1mg/ml BSA, 0.02% sodium azide, 50% glycerol.

May be stored at 4 degree C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degree C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.?

Small volumes of anti-MYL2 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Myosin is composed of six polypeptide chains: two identical heavy chains and two pairs of light chains. Myosin light chain 2 (MLC2), also known as myosin regulatory light chain (MRLC or RLC, LC20), has many isoforms depending on its distribution. In smooth muscle, MLC2 is phosphorylated at Thr18 and Ser19 by myosin light chain kinase (MLCK) in a Ca2+/calmodulindependent manner (1). This phosphorylation is correlated with myosin ATPase activity and smooth muscle contraction (2). ROCK also phosphorylates Ser19 of smooth muscle MLC2, which regulates the assembly of stress fibers (3). Phosphorylation of smooth muscle MLC2 at Ser1/Ser2 and Ser9 by PKC and cdc2 has been reported to inhibit myosin ATPase activity (4,5). Phosphorylation by cdc2 controls the timing of cytokinesis (5). Transgenic mice lacking phosphorylation sites on the cardiac muscle isoform show morphological and functional abnormalities (6).

Antibodies; Abs to Myosin

Western Blot (WB), Immunofluorescence (IF), Immunocytochemistry (ICC)

Other applications not tested.

Western Blot: 1:1000 Incubate membrane with diluted antibody in 5% nonfat dry milk, 1X TBS, 0.1% Tween-20 at 4°C with gentle shaking, overnight.
Immunofluorescence: 1:200

Optimal dilutions to be determined by the researcher.

Western blot analysis of extracts from HEK293, C212, and C6 cells, untreated (-) or lamda phosphatase treated (+), using Myosin Light Chain 2 Antibody (upper) or MBS609646 (lower).

Confocal immunofluorescent images of HeLa cells, untreated (left) or phosphatase-treated (right), labeled with MBS609646 (green).
Actin filaments have been labeled with Alexa Fluor 555 phalloidin (red). Blue pseudocolor = DRAQ5.

myosin, light chain 2, regulatory, cardiac, slow

myosin regulatory light chain 2, ventricular/cardiac muscle isoform; MLC-2; MLC-2v; RLC of myosin; myosin light chain 2; regulatory light chain of myosin; cardiac ventricular myosin light chain 2; slow cardiac myosin regulatory light chain 2; myosin, light polypeptide 2, regulatory, cardiac, slow

Myosin regulatory light chain 2, ventricular/cardiac muscle isoform

MLRV_HUMAN

Thus gene encodes the regulatory light chain associated with cardiac myosin beta (or slow) heavy chain. Ca+ triggers the phosphorylation of regulatory light chain that in turn triggers contraction. Mutations in this gene are associated with mid-left ventricular chamber type hypertrophic cardiomyopathy. [provided by RefSeq]

MRLC2V: myosin regulatory light chain 2, ventricular/cardiac muscle isoform. Ca+ triggers the phosphorylation of regulatory light chain that in turn triggers contraction. Mutations in MYL2 are associated with mid-left ventricular chamber type hypertrophic cardiomyopathy.

Protein type: Contractile

Chromosomal Location of Human Ortholog: 12q24.11

Cellular Component: sarcomere; cytoskeleton; myofibril; myosin complex; cytosol; A band; actin cytoskeleton

Molecular Function: actin monomer binding; protein binding; structural constituent of muscle; calcium ion binding; myosin heavy chain binding

Biological Process: muscle cell fate specification; heart contraction; regulation of striated muscle contraction; ventricular cardiac muscle morphogenesis; cardiac myofibril assembly; negative regulation of cell growth; muscle fiber development; cardiac muscle contraction; post-embryonic development; muscle filament sliding

Disease: Cardiomyopathy, Familial Hypertrophic, 10

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.